Entrada Therapeutics (TRDA) Accounts Payables (2020 - 2026)

Entrada Therapeutics has reported Accounts Payables for 7 years, with the latest figure at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 33.91% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $2.9 million (up 33.91% YoY), and the FY2025 full-year result was $2.3 million, down 46.25% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.9 million, up from $2.3 million in the prior quarter.
• The five-year high for Accounts Payables was $6.5 million in Q1 2023, with the low at $752000.0 in Q3 2023.
• Average Accounts Payables over 5 years is $2.9 million, with a median of $2.5 million recorded in 2024.
• Year-over-year, Accounts Payables soared 748.44% in 2022 and slumped 60.97% in 2024.
• Tracing TRDA's Accounts Payables over 5 years: stood at $6.0 million in 2022, then tumbled by 45.29% to $3.3 million in 2023, then advanced by 29.97% to $4.3 million in 2024, then plunged by 46.25% to $2.3 million in 2025, then rose by 28.0% to $2.9 million in 2026.
• The last three Accounts Payables figures came in at $2.9 million (Q1 2026), $2.3 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.

Peer Comparison